Boston Scientific Co
BSX
Real-time BATS EXCHANGE - 08/17 08:57:49 pm
34.515USD
+0.61%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Sales9 0489 849
EBITDA2 5472 820
Operating profit (EBIT)2 2682 487
Pre-Tax Profit (EBT)--
Net income1041 389
EPS ( $ )0,081,04
Dividend per Share ( $ )--
Yield--
Announcement Date02/01/2018
11:30am
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Debt5 4284 650
Finance--
Operating income (EBITDA)2 5472 820
Leverage
(Debt/EBITDA)
2,13x1,65x
Capital Expenditure319342
Book Value Per Share (BVPS)5,10 $5,96 $
Cash Flow per Share1,02 $1,19 $
Announcement Date02/01/2018
11:30am
-
Balance Sheet Analysis
Financial Ratios
Size 2018e 2019e
Capitalization 48 250 M$ -
Entreprise Value (EV) 52 900 M$ 51 878 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS) 33,1x 29,3x
Capitalization / Revenue 4,90x 4,58x
EV / Revenue 5,37x 4,92x
EV / EBITDA 18,8x 16,6x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 5,75x 4,84x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) 25,2% 26,5%
operating Leverage (Delta EBIT / Delta Sales) 1,09x 1,76x
Net Margin (Net Profit / Revenue) 14,1% 15,8%
ROA (Net Profit / Asset) 8,30% 9,55%
ROE (Net Profit / Equities) 22,3% 25,7%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   3,48% 3,37%
Cash Flow / Sales 16,8% 26,5%
Capital Intensity (Assets / Sales) 1,70x 1,66x
Financial Leverage (Net Debt / EBITDA) 1,65x 1,16x
Price Earning Ratio
BNA & Dividende